Trial Profile
A Multicenter, Open-Label, Dose-Escalating Phase I Trial of the DNA-PK Inhibitor MSC2490484A in Subjects With Advanced Solid Tumors or Chronic Lymphocytic Leukemia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Nov 2020
Price :
$35
*
At a glance
- Drugs Peposertib (Primary)
- Indications Chronic lymphocytic leukaemia; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Merck KGaA
- 24 Nov 2020 Results published in the British Journal of Cancer.
- 25 Oct 2017 Status changed from active, no longer recruiting to completed.
- 11 Sep 2017 Trial focus has been changed from TU and AR to AR as primary endpoint 'overall response' removed from the study.